GlassScriptPhysician profile
Kimberly Presnell
NPI 1992314157
$3,444.25
in general payments reported to CMS, 2019-2025
38 companies · $2,050 in 2025
The $2,050 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.71 · 2022: $537 · 2023: $49.03 · 2024: $794 · 2025: $2,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,678 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,677.52 |
| Education | $216.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $320.80 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $283.00 | 2022-2025 | |
| Lilly USA, LLC | $263.42 | 2022-2025 | Jaypirca, Verzenio, Jardiance |
| Pfizer INC. | $176.28 | 2024-2025 | |
| Incyte Corporation | $172.24 | 2025 | Jakafi, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $162.01 | 2024-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $153.66 | 2022-2025 | Keytruda |
| Avanos Medical | $137.63 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $136.17 | 2021-2025 | Imfinzi, Enhertu |
| Jazz Pharmaceuticals INC. | $121.91 | 2024-2025 | |
| Exelixis INC. | $121.88 | 2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $106.05 | 2025 | Fruzaqla, Vpriv, Ninlaro |
| Celgene Corporation | $104.50 | 2025 | Opdualag, Reblozyl |
| Glaxosmithkline, LLC. | $104.48 | 2024-2025 | Ojjaara |
| Gilead Sciences, INC. | $101.15 | 2024-2025 | Trodelvy |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $100.72 | 2024-2025 | Carvykti, Tecvayli, Rybrevant |
| Kite Pharma, INC. | $94.24 | 2025 | Yescarta |
| Sobi, INC | $84.24 | 2024-2025 | |
| Astellas Pharma US INC | $79.21 | 2024-2025 | Padcev, Xtandi |
| Beone Medicines USA, INC. | $69.67 | 2025 | Brukinsa |
| Puma Biotechnology, INC. | $60.35 | 2024-2025 | |
| Daiichi Sankyo INC. | $59.40 | 2024-2025 | Enhertu |
| Kyowa Kirin, INC. | $57.66 | 2025 | |
| Genmab U.S., INC. | $52.89 | 2024-2025 | Epkinly |
| Emd Serono, INC. | $41.84 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $32.80 | 2024-2025 | Pyrukynd |
| Dexcom, INC. | $30.78 | 2022-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $30.65 | 2022 | |
| Stemline Therapeutics INC. | $27.79 | 2025 | Orserdu |
| Geron Corporation | $22.19 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $20.41 | 2025 | Monoferric |
| Abbott Laboratories | $19.06 | 2022 | |
| Aveo Pharmaceuticals, INC. | $17.84 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.36 | 2025 | |
| Adaptive Biotechnologies Corporation | $16.35 | 2025 | Clonoseq |
| Sumitomo Pharma America, INC. | $15.12 | 2025 | Orgovyx |
| Eisai INC. | $14.56 | 2025 | |
| Kci USA, INC. | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Presnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.